Vassilios Papademetriou

List of Publications by Citations

239 papers	10,682 citations	53 h-index	98 g-index
260 ext. papers	12,078 ext. citations	5.2 avg, IF	5.63 L-index

#	Paper	IF	Citations
239	Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *Journal of Clinical Hypertension*, **2002**, 4, 393-404	2.3	720
238	Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2001**, 285, 1585-91	27.4	708
237	Prognostic significance of left ventricular mass change during treatment of hypertension. *JAMA - Journal of the American Medical Association*, **2004**, 292, 2350-6	27.4	592
236	Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. *Circulation*, **2004**, 110, 1456-62	16.7	379
235	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. *Lancet, The*, **2018**, 391, 2346-2355	40	358
234	Exercise capacity and mortality in black and white men. *Circulation*, **2008**, 117, 614-22	16.7	296
233	Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. *JAMA - Journal of the American Medical Association*, **2005**, 293, 1595-608	27.4	294
232	Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. *Headache*, **2004**, 44, 414-25	4.2	274
231	Effects of Intensive BP Control in CKD. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 2812-2823	12.7	234
230	Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. *New England Journal of Medicine*, **1995**, 333, 1462-7	59.2	234
229	Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. *European Heart Journal*, **2013**, 34, 2132-40	9.5	230
228	Exercise capacity and mortality in older men: a 20-year follow-up study. *Circulation*, **2010**, 122, 790-7	16.7	230
227	Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population : the LIFE study. *Hypertension*, **2000**, 35, 6-12	8.5	200
226	Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. *Circulation*, **2002**, 105, 1071-6	16.7	154
225	Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint. *American Journal of Cardiology*, **2000**, 85, 466-72	3	140
224	Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: The study on cognition and prognosis in the elderly (SCOPE). *Journal of the American College of Cardiology*, **2004**, 44, 1175-1180	15.1	135
223	Analysis of T-wave morphology from the 12-lead electrocardiogram for prediction of long-term prognosis in male US veterans. *Circulation*, **2002**, 105, 1066-70	16.7	130

222	Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. *Kidney International*, **2015**, 87, 649-59	9.9	124
221	Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. *Journal of Hypertension*, **2002**, 20, 405-12	1.9	123
220	Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. *Circulation*, **2006**, 113, 2201-10	16.7	114
219	Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. *American Journal of Cardiology*, **2005**, 96, 946-51	3	107
218	Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. *American Heart Journal*, **2002**, 143, 319-26	4.9	107
217	Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). *American Journal of Cardiology*, **2014**, 114, 1217-22	3	99
216	Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias. *American Journal of Cardiology*, **1983**, 52, 1017-22	3	98
215	Exceptional early blood pressure control rates: the ACCOMPLISH trial. *Blood Pressure*, **2007**, 16, 80-6	1.7	97
214	Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. *Blood Pressure*, **2001**, 10, 74-82	1.7	97
213	Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control. *Circulation*, **2018**, 137, 134-143	16.7	89
212	Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Hypertension*, **2001**, 37, 19-27	8.5	87
211	Gender differences in hypertension: myths and reality. *Current Hypertension Reports*, **2013**, 15, 321-30	4.7	86
210	Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. *Journal of Hypertension*, **2001**, 19, 1883-91	1.9	86
209	Effects of mental stress on coronary epicardial vasomotion and flow velocity in coronary artery disease: relationship with hemodynamic stress responses. *Journal of the American College of Cardiology*, **2001**, 37, 1359-66	15.1	85
208	Exercise capacity and progression from prehypertension to hypertension. *Hypertension*, **2012**, 60, 333-8	8.5	83
207	Pathophysiology of resistant hypertension: the role of sympathetic nervous system. *International Journal of Hypertension*, **2011**, 2011, 642416	2.4	83
206	Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. *Circulation*, **2002**, 106, 227-32	16.7	70
205	Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. *American Journal of Medicine*, **1993**, 94, 181-7	2.4	69

204	Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. *American Heart Journal*, **1995**, 130, 359-66	4.9	68
203	Exercise as hypertension therapy. *Cardiology Clinics*, **2001**, 19, 507-16	2.5	67
202	Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. *Hypertension*, **2012**, 59, 926-33	8.5	66
201	Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study. *Journal of Hypertension*, **2003**, 21, 781-7	1.9	65
200	Blood pressure control among US veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository. *Circulation*, **2012**, 125, 2462-8	16.7	64
199	The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. *Blood Pressure*, **2005**, 14, 31-7	1.7	64
198	Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. *Journal of the American College of Surgeons*, **2010**, 211, 384-90	4.4	63
197	Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. *Journal of Hypertension*, **2002**, 20, 1445-50	1.9	63
196	Echocardiographic assessment by computer-assisted analysis of diastolic left ventricular function and hypertrophy in borderline or mild systemic hypertension. *American Journal of Cardiology*, **1985**, 56, 546-50	3	62
195	Renal sympathetic denervation and systemic hypertension. *American Journal of Cardiology*, **2010**, 105, 570-6	3	61
194	Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). *Journal of the American College of Cardiology*, **2004**, 44, 1175-80	15.1	61
193	Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. *Journal of Hypertension*, **2000**, 18, 1129-38	1.9	60
192	Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. *Journal of Hypertension*, **2014**, 32, 415-22	1.9	59
191	Hypertension crisis. *Blood Pressure*, **2010**, 19, 328-36	1.7	56
190	Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system. *Hypertension*, **2014**, 64, 565-72	8.5	55
189	Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease: A Secondary Analysis of a Randomized Trial. *Annals of Internal Medicine*, **2017**, 167, 375-383	8	54
188	Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. *Diabetes Care*, **2017**,	14.6	53
187	Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). *American Journal of Cardiology*, **2002**, 89, 337-41	3	53

186	ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study. *American Journal of Kidney Diseases*, **2010**, 55, 1050-9	7.4	51
185	Common secondary causes of resistant hypertension and rational for treatment. *International Journal of Hypertension*, **2011**, 2011, 236239	2.4	49
184	Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). *Hypertension*, **2017**, 70, 751-758	8.5	48
183	Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study. *Journal of Hypertension*, **2009**, 27, 744-52	1.9	47
182	Exercise and hypertension. *Coronary Artery Disease*, **2000**, 11, 99-102	1.4	44
181	Thiazide Therapy Is Not a Cause of Arrhythmia in Patients With Systemic Hypertension. *Archives of Internal Medicine*, **1988**, 148, 1272		44
180	Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions. *Circulation*, **2014**, 129, 1440-51	16.7	40
179	Cardiorespiratory fitness and coronary heart disease risk factor association in women. *Journal of the American College of Cardiology*, **1995**, 26, 358-64	15.1	40
178	Diuretics, hypokalemia, and cardiac arrhythmias: a critical analysis. *American Heart Journal*, **1986**, 111, 1217-24	4.9	40
177	Air pollution and arterial hypertension. A new risk factor is in the air. *Journal of the American Society of Hypertension*, **2017**, 11, 709-715		39
176	Renal denervation and Symplicity HTN-3: "Dubium sapientiae initium" (doubt is the beginning of wisdom). *Circulation Research*, **2014**, 115, 211-4	15.7	39
175	Effect of diuretic therapy on ventricular arrhythmias in hypertensive patients with or without left ventricular hypertrophy. *American Heart Journal*, **1985**, 110, 595-9	4.9	38
174	Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. *Journal of Hypertension*, **2010**, 28, 2299-308	1.9	37
173	Catheter-based renal sympathetic denervation exerts acute and chronic effects on renal hemodynamics in swine. *International Journal of Cardiology*, **2013**, 168, 987-92	3.2	34
172	Albuminuria and cognitive decline in people with diabetes and normal renal function. *Clinical Journal of the American Society of Nephrology: CJASN*, **2013**, 8, 1907-14	6.9	34
171	Effects of aerobic training on exaggerated blood pressure response to exercise in African-Americans with severe systemic hypertension treated with indapamide +/- verapamil +/- enalapril. *American Journal of Cardiology*, **1997**, 79, 1424-6	3	34
170	A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. *Blood Pressure*, **2009**, 18, 261-7	1.7	33
169	In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. *Journal of Hypertension*, **2010**, 28, 1541-6	1.9	33

168	Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. *Hypertension*, **2003**, 41, 75-82	8.5	33
167	Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. *Journal of Clinical Hypertension*, **2013**, 15, 333-6	2.3	32
166	Chronic heart failure and exercise. *American Heart Journal*, **2000**, 140, 21-8	4.9	32
165	Exercise blood pressure response and left ventricular hypertrophy. *American Journal of Hypertension*, **1989**, 2, 114-6	2.3	32
164	Body mass index, exercise capacity, and mortality risk in male veterans with hypertension. *American Journal of Hypertension*, **2012**, 25, 444-50	2.3	31
163	Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study). *American Journal of Cardiology*, **2010**, 106, 999-1005	3	31
162	Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study. *American Heart Journal*, **2003**, 145, 919-25	4.9	30
161	Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. *American Journal of Hypertension*, **2005**, 18, 3-12	2.3	29
160	Effect of Intensive Blood Pressure Control on Gait Speed and Mobility Limitation in Adults 75 Years or Older: A Randomized Clinical Trial. *JAMA Internal Medicine*, **2017**, 177, 500-507	11.5	28
159	Catheter-based renal denervation for resistant hypertension: Twenty-four month results of the EnligHTN I first-in-human study using a multi-electrode ablation system. *International Journal of Cardiology*, **2015**, 201, 345-50	3.2	28
158	Attended and Unattended Automated Office Blood Pressure Measurements Have Better Agreement With Ambulatory Monitoring Than Conventional Office Readings. *Journal of the American Heart Association*, **2018**, 7,	6	28
157	Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions. *International Journal of Cardiology*, **2014**, 172, 29-35	3.2	28
156	Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group. *Journal of the American College of Cardiology*, **1997**, 30, 1802-8	15.1	28
155	Effects of moderate intensity exercise on serum lipids in African-American men with severe systemic hypertension. *American Journal of Cardiology*, **1998**, 81, 732-5	3	28
154	Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease. *American Journal of Nephrology*, **2016**, 43, 271-80	4.6	28
153	Therapeutic adherence in the elderly: transdermal clonidine compared to oral verapamil for hypertension. *American Journal of Medicine*, **1991**, 91, 22S-28S	2.4	27
152	Effects of continuous positive airway pressure on blood pressure in hypertensive patients with obstructive sleep apnea: a 3-year follow-up. *Journal of Hypertension*, **2013**, 31, 352-60	1.9	27
151	Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions. *Expert Opinion on Therapeutic Targets*, **2009**, 13, 413-25	6.4	26

150	Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. *Hypertension*, **2005**, 46, 492-9	8.5	25
149	Orthostatic hypotension: From pathophysiology to clinical applications and therapeutic considerations. *Journal of Clinical Hypertension*, **2019**, 21, 546-554	2.3	24
148	Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. *Journal of the American Society of Nephrology: JASN*, **2019**, 30, 1523-1533	12.7	24
147	Resistant hypertension: diagnosis and management. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2006**, 11, 113-8	2.6	24
146	Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levels. HIT Investigators. Department of Veterans Affairs HDL Intervention Trial. *American Heart Journal*, **1998**, 136, 734-40	4.9	24
145	Effect of Intensive Blood Pressure Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial. *American Journal of Hypertension*, **2016**, 29, 1276-1282	2.3	22
144	Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension. *International Journal of Hypertension*, **2011**, 2011, 196518	2.4	22
143	Renal sympathetic denervation in hypertension. *Current Opinion in Nephrology and Hypertension*, **2011**, 20, 647-53	3.5	22
142	Systolic-diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the Cardiovascular Health Study. *International Journal of Cardiology*, **2017**, 235, 11-16	3.2	21
141	Carotid baroreceptor activation for the treatment of resistant hypertension and heart failure. *Current Hypertension Reports*, **2012**, 14, 238-46	4.7	21
140	Heart rate recovery, exercise capacity, and mortality risk in male veterans. *European Journal of Preventive Cardiology*, **2012**, 19, 177-84	3.9	21
139	PhysiciansQperceptions and adherence to guidelines for the management of hypertension: a national, multicentre, prospective study. *International Journal of Hypertension*, **2012**, 2012, 503821	2.4	21
138	Beta-blockers in the management of hypertension: focus on nebivolol. *Expert Review of Cardiovascular Therapy*, **2008**, 6, 471-9	2.5	21
137	Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). *American Journal of Cardiology*, **2004**, 94, 1076-80	3	21
136	Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. *American Heart Journal*, **2004**, 148, 538-44	4.9	21
135	Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2009**, 16, 242-8		20
134	Cardiovascular risk assessment and triptans. *Headache*, **2004**, 44 Suppl 1, S31-9	4.2	20
133	Transient coronary occlusion with mental stress. *American Heart Journal*, **1996**, 132, 1299-301	4.9	20

132	Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study. *Hypertension*, **2015**, 66, 945-53	8.5	19
131	Statin therapy, fitness, and mortality risk in middle-aged hypertensive male veterans. *American Journal of Hypertension*, **2014**, 27, 422-30	2.3	19
130	Carotid baroreceptor stimulation for the treatment of resistant hypertension. *International Journal of Hypertension*, **2011**, 2011, 964394	2.4	19
129	Effects of multielectrode renal denervation on elevated sympathetic nerve activity and insulin resistance in metabolic syndrome. *Journal of Hypertension*, **2017**, 35, 1100-1108	1.9	17
128	Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and meta-analysis of randomized, sham-controlled, catheter-based trials. *Journal of Clinical Hypertension*, **2020**, 22, 572-584	2.3	17
127	Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. *Diabetes Care*, **2014**, 37, 686-93	14.6	17
126	renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention Trial. *Kidney International Reports*, **2017**, 2, 713-720	4.1	17
125	Relationship of ambulatory arterial stiffness index with blood pressure response to exercise in the early stages of hypertension. *Blood Pressure Monitoring*, **2010**, 15, 132-8	1.3	17
124	Aggressive blood pressure control and stroke prevention: role of calcium channel blockers. *Journal of Hypertension*, **2008**, 26, 844-52	1.9	17
123	Catheter-based radio-frequency renal nerve denervation lowers blood pressure in obese hypertensive swine model. *Journal of Hypertension*, **2016**, 34, 1854-62	1.9	16
122	Effects of multielectrode renal denervation on cardiac and neurohumoral adaptations in resistant hypertension with cardiac hypertrophy: an EnligHTN I substudy. *Journal of Hypertension*, **2015**, 33, 346-53	1.9	16
121	Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension. *American Journal of Cardiology*, **2009**, 103, 273-8	3	16
120	Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction. *American Heart Journal*, **2009**, 157, S17-23	4.9	16
119	Early changes in plasma and urinary potassium in diuretic-treated patients with systemic hypertension. *American Journal of Cardiology*, **1984**, 54, 1015-9	3	16
118	Effect of Intensive Blood Pressure Reduction on Left Ventricular Mass, Structure, Function, and Fibrosis in the SPRINT-HEART. *Hypertension*, **2019**, HYPERTENSIONAHA11913073	8.5	15
117	Factorial antihypertensive study of an extended-release metoprolol and hydrochlorothiazide combination. *American Journal of Hypertension*, **2006**, 19, 1217-25	2.3	15
116	Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. *Clinical Journal of the American Society of Nephrology: CJASN*, **2018**, 13, 1693-1702	6.9	15
115	Home, automated office, and conventional office blood pressure as predictors of cardiovascular risk. *Journal of the American Society of Hypertension*, **2017**, 11, 165-170.e2		14

114	Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events. *American Heart Journal*, **2009**, 157, S24-30	4.9	14
113	Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). *American Journal of Cardiology*, **2002**, 89, 399-402	3	14
112	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in African-American patients with hypertension. *Journal of Clinical Hypertension*, **2004**, 6, 310-4	2.3	14
111	Halting arterial aging in patients with cardiovascular disease: hypolipidemic and antihypertensive therapy. *Current Pharmaceutical Design*, **2014**, 20, 6339-49	3.3	14
110	Impact of multi-electrode renal sympathetic denervation on short-term blood pressure variability in patients with drug-resistant hypertension. Insights from the EnligHTN I study. *International Journal of Cardiology*, **2015**, 180, 237-42	3.2	13
109	Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. *Journal of Hypertension*, **2008**, 26, 1472-6	1.9	13
108	How dangerous are diuretics?. *Drugs*, **1985**, 30, 469-74	12.1	13
107	Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients With Hypertension. *Journal of the American Heart Association*, **2017**, 6,	6	12
106	From @ssential Hypertension to intensive blood pressure lowering: the pros and cons of lower target values. *European Heart Journal*, **2017**, 38, 3258-3271	9.5	12
105	Benefits from treatment and control of patients with resistant hypertension. *International Journal of Hypertension*, **2010**, 2011, 318549	2.4	12
104	Electrocardiographic abnormalities suggestive of myocardial ischemia during upper gastrointestinal bleeding. *American Journal of Cardiology*, **1995**, 75, 312-4	3	12
103	Now That Renal Denervation Works, How Do We Proceed?. *Circulation Research*, **2019**, 124, 693-695	15.7	11
102	Evaluation and treatment of resistant or difficult-to-control hypertension. *Journal of Clinical Hypertension*, **2008**, 10, 837-43	2.3	11
101	Low-dose combination treatment for hypertension versus single-drug treatment-bisoprolol/hydrochlorothiazide versus amlodipine, enalapril, and placebo: combined analysis of comparative studies. *American Journal of Therapeutics*, **1998**, 5, 313-21	1	11
100	Effects of diuretic therapy and exercise-related arrhythmias in systemic hypertension. *American Journal of Cardiology*, **1989**, 64, 1152-6	3	11
99	Unobserved automated office BP is similar to other clinic BP measurements: A prospective randomized study. *Journal of Clinical Hypertension*, **2018**, 20, 1411-1416	2.3	11
98	Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. *American Journal of Nephrology*, **2017**, 45, 136-145	4.6	10
97	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. *American Journal of Medicine*, **2017**, 130, 1465.e27-1465.e39	2.4	10

96	Renal and cardiac effects of renal sympathetic denervation and carotid baroreceptor stimulation. *Current Vascular Pharmacology*, **2014**, 12, 55-62	3.3	10
95	Relation of impaired coronary microcirculation to increased urine albumin excretion in patients with systemic hypertension and no epicardial coronary arterial narrowing. *American Journal of Cardiology*, **2012**, 109, 1026-30	3	10
94	National utilization of antihypertensive medications from 2000 to 2006 in the Veterans Health Administration: focus on thiazide diuretics. *Journal of Clinical Hypertension*, **2008**, 10, 770-8	2.3	10
93	Candesartan cilexetil in cardiovascular disease. *Expert Review of Cardiovascular Therapy*, **2004**, 2, 829-35	2.5	10
92	Improvement in All-Cause Mortality With Blood Pressure Control in a Group of US Veterans With Drug-Resistant Hypertension. *Journal of Clinical Hypertension*, **2016**, 18, 33-9	2.3	10
91	PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT. *Clinical Journal of the American Society of Nephrology: CJASN*, **2018**, 13, 1816-1824	6.9	10
90	Electrical stimulation of the renal arterial nerves does not unmask the blindness of renal denervation procedure in swine. *International Journal of Cardiology*, **2014**, 176, 1061-3	3.2	9
89	Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). *Blood Pressure*, **2009**, 18, 180-6	1.7	9
88	Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study. *Hypertension*, **2006**, 47, 868-73	8.5	9
87	From hypertension to heart failure. *Journal of Clinical Hypertension*, **2004**, 6, 14-7	2.3	9
86	Renal Fibromuscular Dysplasia: A Not So Common Entity of Secondary Hypertension. *Journal of Clinical Hypertension*, **2016**, 18, 240-6	2.3	9
85	Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension: a meta-analysis. *Journal of Hypertension*, **2017**, 35, 1750-1757	1.9	8
84	Morning Surge and Peak Morning Ambulatory Blood Pressure Versus Automated Office Blood Pressure in Predicting Cardiovascular Disease. *High Blood Pressure and Cardiovascular Prevention*, **2019**, 26, 209-215	2.9	8
83	Metoprolol succinate combination in the treatment of hypertension. *Angiology*, **2009**, 60, 608-13	2.1	8
82	Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. *American Journal of Hypertension*, **2003**, 16, 180-6	2.3	8
81	Effectiveness of Potassium Chloride or Triamterene in Thiazide Hypokalemia. *Archives of Internal Medicine*, **1985**, 145, 1986		8
80	Device-Based Therapy for Drug-Resistant Hypertension: An Update. *Current Hypertension Reports*, **2016**, 18, 64	4.7	8
79	Attended Versus Unattended Automated Office Blood Pressure: A Systematic Review and Meta-analysis. *High Blood Pressure and Cardiovascular Prevention*, **2019**, 26, 293-303	2.9	7

78	Implantation of a carotid baroreceptor stimulator in patients with pacemakers and hypertension. *PACE - Pacing and Clinical Electrophysiology*, **2011**, 34, 354-6	1.6	7
77	Efficacy of low-dose combination of bisoprolol/hydrochlorothiazide compared with amlodipine and enalapril in men and women with essential hypertension. *American Journal of Cardiology*, **1998**, 81, 1363-5	3	7
76	The role of exercise in the control of hypertension and cardiovascular risk. *Current Opinion in Nephrology and Hypertension*, **1996**, 5, B153	3.5	7
75	Effect of hydrochlorothiazide therapy on cardiac arrhythmias in African-American men with systemic hypertension and moderate to severe left ventricular hypertrophy. *American Journal of Cardiology*, **1996**, 78, 886-9	3	7
74	Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus. *Vascular Health and Risk Management*, **2019**, 15, 365-373	4.4	6
73	Screening for Primary Aldosteronism: Whom and How?. *Journal of Clinical Hypertension*, **2015**, 17, 547-8	2.3	6
72	Apelin and relaxin plasma levels in young healthy offspring of patients with essential hypertension. *Journal of Clinical Hypertension*, **2014**, 16, 198-201	2.3	6
71	Impressive blood pressure and heart rate response after percutaneous renal denervation in a woman with morbid obesity and severe drug-resistant hypertension. *Journal of Clinical Hypertension*, **2013**, 15, 852-5	2.3	6
70	Metabolic side effects and cardiovascular events of diuretics: should a diuretic remain the first choice therapy in hypertension treatment? The case of yes. *Clinical and Experimental Hypertension*, **2007**, 29, 503-16	2.2	6
69	Comparative prognostic value of systolic, diastolic, and pulse pressure. *American Journal of Cardiology*, **2003**, 91, 433-5	3	6
68	Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study). *American Journal of Cardiology*, **2005**, 95, 280-3	3	6
67	Effects of diltiazem, metoprolol, enalapril and hydrochlorothiazide on frequency of ventricular premature complexes. *American Journal of Cardiology*, **1994**, 73, 242-6	3	6
66	Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?. *Current Treatment Options in Cardiovascular Medicine*, **2017**, 19, 39	2.1	5
65	Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?. *Current Vascular Pharmacology*, **2017**, 16, 66-69	3.3	5
64	Cardiovascular morbidity of severe resistant hypertension among treated uncontrolled hypertensives: a 4-year follow-up study. *Journal of Human Hypertension*, **2018**, 32, 487-493	2.6	5
63	Renal Sympathetic Denervation: Hibernation or Resurrection?. *Cardiology*, **2016**, 135, 87-97	1.6	5
62	Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?. *Current Vascular Pharmacology*, **2017**, 16, 30-43	3.3	5
61	Hypertrophic and hypertensive hypertrophic cardiomyopathy--a true association?. *Angiology*, **2010**, 61, 92-9	2.1	5

60	Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study. *American Journal of Hypertension*, **2008**, 21, 701-7	2.3	5
59	Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria: Analyses from SPRINT. *Clinical Journal of the American Society of Nephrology: CJASN*, **2020**, 15, 1121-1128	6.9	5
58	A case of influenza type a myocarditis that presents with ST elevation MI, cardiogenic shock, acute renal failure, and rhabdomyolysis and with rapid recovery after treatment with oseltamivir and intra-aortic balloon pump support. *Cardiovascular Revascularization Medicine*, **2018**, 19, 37-42	1.6	4
57	Non-interventional management of resistant hypertension. *World Journal of Cardiology*, **2014**, 6, 1080-90	2.1	4
56	Low-dose fixed combination of bisoprolol/hydrochlorothiazide as first line for hypertension: a review of the rationale and clinical evidence. *Angiology*, **2009**, 60, 601-7	2.1	4
55	Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: integrating vascular dysfunction. *Expert Opinion on Therapeutic Targets*, **2011**, 15, 1347-53	6.4	4
54	Targeting angiotensin II type I receptors to reduce the risk of stroke in patients with hypertension. *Expert Opinion on Therapeutic Targets*, **2006**, 10, 231-7	6.4	4
53	Aspirin under fire: aspirin use in the primary prevention of coronary heart disease. *Pharmacotherapy*, **2005**, 25, 847-61	5.8	4
52	Hypertension and Atherosclerosis: Pathophysiology, Mechanisms and Benefits of BP Control **2016**, 201-216		4
51	The Role of Angiogenesis Inhibitors in Hypertension: Following "Ariadne© Thread". *American Journal of Hypertension*, **2018**, 31, 961-969	2.3	4
50	Renal nerve ablation for resistant hypertension: the dust has not yet settled. *Journal of Clinical Hypertension*, **2014**, 16, 399-400	2.3	3
49	Difficult-to-Treat or Resistant Hypertension: Etiology, Pathophysiology, and Innovative Therapies. *International Journal of Hypertension*, **2011**, 2011, 438198	2.4	3
48	Renal denervation for sleep apnea and resistant hypertension: alternative or complementary to effective continuous positive airway pressure treatment?. *Hypertension*, **2011**, 58, e191; author reply e192	8.5	3
47	Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure control. *Expert Opinion on Pharmacotherapy*, **2009**, 10, 955-66	4	3
46	Electrocardiographic and echocardiographic detection of myocardial infarction in patients with left-ventricular hypertrophy. The LIFE Study. *American Journal of Hypertension*, **2007**, 20, 771-6	2.3	3
45	Losartan in cardiovascular disease. *Future Cardiology*, **2005**, 1, 433-46	1.3	3
44	Regression of hypertensive left ventricular hypertrophy by angiotensin receptor blockade versus beta-blockade: the LIFE trial. *American Journal of Hypertension*, **2002**, 15, A15	2.3	3
43	The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction. *Current Pharmaceutical Design*, **2018**, 24, 5517-5524	3.3	3

42	Inhibition of the renin-angiotensin system in the cardiorenal syndrome with anaemia: a double-edged sword. *Journal of Hypertension*, **2019**, 37, 2145-2153	1.9	3
41	Primary Aldosteronism: Novel Insights. *Current Hypertension Reviews*, **2020**, 16, 19-23	2.3	3
40	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium.. *Circulation*, **2022**, 145, 847-863	16.7	3
39	Insomnia and hypertension: A misty landscape. *Journal of Clinical Hypertension*, **2019**, 21, 835-837	2.3	2
38	Telmisartan for prevention of cardiovascular events. *New England Journal of Medicine*, **2009**, 360, 302; author reply 303	59.2	2
37	A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. *Blood Pressure*, **2009**, 18, 261-267	1.7	2
36	Protective effects of angiotensin-converting enzyme inhibitors in high-risk African American men with coronary heart disease. *Journal of Clinical Hypertension*, **2009**, 11, 621-6	2.3	2
35	Left Ventricular Hypertrophy and Mortality Risk in Male Veteran Patients at High Cardiovascular Risk. *American Journal of Cardiology*, **2020**, 125, 887-893	3	2
34	Prognostic relevance of visit-to-visit office blood pressure variability in Systolic Blood Pressure Intervention Trial: Same data, different conclusions?. *Journal of Clinical Hypertension*, **2018**, 20, 1644-1645	2.3	2
33	Olmesartan worsening known thrombocytopenia. A rare side effect of antihypertensive drugs. *Hellenic Journal of Cardiology*, **2017**, 58, 96-97	2.1	1
32	Regarding "Severe bilateral renal artery stenosis after transluminal radiofrequency ablation of renal sympathetic nerve plexus". *Journal of Vascular Surgery*, **2015**, 62, 539	3.5	1
31	Drug therapy for the patient with resistant hypertension. *Future Cardiology*, **2015**, 11, 191-202	1.3	1
30	Baroreflex activation therapy and resistant hypertension randomization is not enough, you should measure blood pressure appropriately. *Journal of the American College of Cardiology*, **2012**, 59, 541; author reply 541-2	15.1	1
29	On target to dual block RAS?. *Angiology*, **2009**, 60, 739-49	2.1	1
28	Tolerability profile of tasosartan, a long-acting angiotensin II AT1 receptor blocker, in the treatment of patients with essential hypertension. *Current Therapeutic Research*, **1997**, 58, 930-943	2.4	1
27	Does rapidity of blood pressure lowering affect outcomes in hypertension treatment?. *Current Cardiovascular Risk Reports*, **2008**, 2, 255-261	0.9	1
26	Eulogy for Edward D. Freis, MD*. *American Journal of Cardiology*, **2005**, 96, 311-312	3	1
25	Pharmacological Management of Diabetic Nephropathy. *Current Vascular Pharmacology*, **2020**, 18, 139-147	3.3	1

24	Joint ESH excellence centersOnational meeting on renal sympathetic denervation: A Greek expertsO survey. *Hellenic Journal of Cardiology*, **2021**, 62, 355-358	2.1	1
23	Determinants of pulse wave velocity index and potential implementations. *Journal of Clinical Hypertension*, **2019**, 21, 1493-1495	2.3	1
22	The clinical value of automated office blood pressure: What is the latest evidence on attended vs unattended automated readings in clinical practice?. *Journal of Clinical Hypertension*, **2019**, 21, 156-158	2.3	1
21	The Impact of Various Blood Pressure Measurements on Cardiovascular Outcomes. *Current Vascular Pharmacology*, **2021**, 19, 313-322	3.3	0
20	Effect of Intensive Versus Standard Blood Pressure Control on Stroke Subtypes. *Hypertension*, **2021**, 77, 1391-1398	8.5	0
19	Serial changes in vessel walls of renal arteries after catheter-based renal artery denervation: insights from volumetric computed tomography analysis. *International Journal of Nephrology and Renovascular Disease*, **2018**, 11, 259-266	2.5	0
18	The Reply. *American Journal of Medicine*, **2018**, 131, e317	2.4	0
17	Hypertension in Pregnancy: Unanswered Questions. *Current Pharmaceutical Design*, **2021**, 27, 3795-3803	3.3	0
16	Response by Latif et al to Letter Regarding Article, "Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention: Insights From DIVA Trial". *Circulation: Cardiovascular Interventions*, **2020**, 13, e009174	6	
15	Reply. *Journal of Hypertension*, **2017**, 35, 200	1.9	
14	Renal sympathetic denervation resurrected; or NOT?. *Journal of the American Society of Hypertension*, **2017**, 11, 700-703		
13	Response to letter to the editor: "Renal artery stenosis may be responsible for the gradual return of high blood pressure after renal denervation". *Journal of Clinical Hypertension*, **2014**, 16, 314	2.3	
12	Left ventricular hypertrophy: not so much determinant of renal outcome?. *Journal of Hypertension*, **2011**, 29, 622	1.9	
11	Achieving renal denervation: catheter-based and surgical management for neural ablation in the management of hypertension. *Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery*, **2012**, 7, 314-22	1.5	
10	Regional cardiac compression due to a large anaerobic bacterial empyema. *Clinical Cardiology*, **1996**, 19, 332-4	3.3	
9	Diuretics, potassium, and ventricular arrhythmias. *JAMA - Journal of the American Medical Association*, **1992**, 268, 52-3	27.4	
8	Place of Invasive Procedures in Blood Pressure Control. *Updates in Hypertension and Cardiovascular Protection*, **2018**, 853-865	0.1	
7	Sympathetic Renal Denervation Using the EnligHTN Multi-electrode Ablation System: The St Jude Experience **2015**, 69-79		

List of Publications

6	Achieving Renal Denervation: Catheter-Based and Surgical Management for Neural Ablation in the Management of Hypertension. *Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery*, **2012**, 7, 314-322	1.5
5	Selecting Optimum Antihypertensive Therapy **2016**, 217-247	
4	Renal Denervation: A Historical Perspective. *Updates in Hypertension and Cardiovascular Protection*, **2016**, 201-213	0.1
3	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. *International Journal of Cardiology: Hypertension*, **2019**, 3, 100022	1.6
2	The VA Co-operative Studies; The First RCTs in Cardiovascular Disease A Tribute to Edward D. Freis **2019**, 75-88	
1	Hypertension Management in African Americans: The AASK and Other Landmark Trial Application **2019**, 145-154	